卡瑞利珠单抗联合化疗治疗晚期非小细胞肺癌的效果及安全性的真实世界研究
朱露莎1 王松华2 李进冬1▲
1.江苏省泰州市人民医院科研处,江苏泰州 225300;
2.江苏省泰州市人民医院肿瘤科,江苏泰州 225300
Real-world study of the efficacy and safety of Carrelizumab combined with chemotherapy in the treatment of advanced non-small cell lung cancer#br#
ZHU Lusha1 WANG Songhua2 LI Jindong1▲
1.Department of Scientific Research, Taizhou People’s Hospital, Jiangsu Province, Taizhou 225300, China;
2.Department of Oncology, Taizhou People’s Hospital, Jiangsu Province, Taizhou 225300, China
摘要 目的 探讨卡瑞利珠单抗治疗晚期非小细胞肺癌的效果及安全性的真实世界研究。 方法 选取2019年3月至2020年3月江苏省泰州市人民医院收治的接受卡瑞利珠单抗治疗62例晚期非小细胞肺癌患者,根据患者意愿分为单药组(卡瑞利珠单抗,41例)和联合组(卡瑞利珠单抗联合化疗方案,21例)。治疗3个周期后,比较两组的临床疗效,观察两组用药不良反应;随访12个月,观察两组无进展生存期、中位生存时间。 结果 联合组的总有效率高于单药组(P < 0.05)。两组不良反应总发生率比较,差异无统计学意义(P > 0.05)。两组无进展生存率,中位生存时间比较,差异有统计学意义(P < 0.05)。 结论 真实世界研究中卡瑞利珠单抗用于治疗晚期非小细胞肺癌具有良好效果,且联合治疗效果更好。
关键词 :
卡瑞利珠单抗 ,
晚期非小细胞肺癌 ,
化疗 ,
安全性 ,
真实世界研究
Abstract :Objective To explore the real-world study of the efficacy and safety of Carrelizumab in the treatment of advanced non-small cell lung cancer. Methods A total of 62 patients with advanced non-small cell lung cancer treated with Carrelizumab from March 2019 to March 2020 who admitted to the Taizhou People’s Hospital of Jiangsu Province were selected, and according to the wishes of patients, they were divided into single-drug group (Carrelizumab, 41 cases) and combination group (Carrelizumab combined with chemotherapy regimen, 21 cases). After three cycles of treatment, the clinical efficacy of two groups were compared, adverse drug reactions of two groups were observed, and progression-free survival and median survival time of two groups was observed after 12 months of follow up. Results The total effective rate of combination group was higher than that of single-drug group (P < 0.05). There was no statistically significant difference in the total incidence of adverse reactions between two groups (P > 0.05). Progression-free survival rate and median survival time between two groups were statistically significant (P < 0.05). Conclusion Carrelizumab has a good effect in the treatment of advanced non-small cell lung cancer in real-world study, and the combined treatment effect is better.
Key words :
Carrelizumab
Advanced non-small cell lung cancer
Chemotherapy
Safety
Real-world study
基金资助: 江苏省自然科学基金项目(BK20180822)。
通讯作者:
▲通讯作者
作者简介 : 朱露莎(1984.7-),女,硕士,副主任药师;研究方向:药物临床试验。
[1] Duma N,Santana-Davila R,Molina JR. Non-Small Cell Lung Cancer:Epidemiology,Screening,Diagnosis,and Treatment [J]. Mayo Clin Proc,2019,94(8):1623-1640.
[2] 张莉,易成凤,何源,等.化疗周期对埃克替尼一二线化疗耐药的表皮生长因子受体突变不明的非小细胞肺癌临床疗效分析[J].中华肺部疾病杂志:电子版,2019,12(5):79-82.
[3] Arbour KC,Riely GJ. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer:A Review [J]. JAMA,2019,322(8):764-774.
[4] Reck M,Borghaei H,O’Byrne KJ. Nivolumab plus ipilimumab in non-small-cell lung cancer [J]. Future Oncol,2019,15(19):2287-2302.
[5] 李文洁,金发光,袁灿亮,等.同步推量调强放疗联合靶向药物治疗晚期非小细胞肺癌的临床效果[J].中华肺部疾病杂志:电子版,2020,13(4):507-509.
[6] Broderick SR. Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer [J]. Thorac Surg Clin,2020, 30(2):215-220.
[7] Hsu ML,Naidoo J. Principles of Immunotherapy in Non-Small Cell Lung Cancer [J]. Thorac Surg Clin,2020,30(2):187-198.
[8] Judd J,Borghaei H. Combining Immunotherapy and Chem-otherapy for Non-Small Cell Lung Cancer [J]. Thorac Surg Clin,2020,30(2):199-206.
[9] Yan Z,Yao ZH,Yao SN,et al. Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma [J]. Immunotherapy,2020,12(16):1161-1166.
[10] Markham A,Keam SJ. Camrelizumab:First Global Approval [J]. Drugs,2019,79(12):1355-1361.
[11] 薛朝军,余克富,靳会欣,等.5种程序性细胞死亡蛋白1抑制剂的Mini卫生技术评估[J].中国医院药学杂志,2020,40(15):41-45,65.
[12] 王书航,王洁.2018年V3版NCCN非小细胞肺癌指南更新要点解读[J].华西医学,2018,33(4):388-392.
[13] 张百红,岳红云.实体瘤疗效评价标准简介[J].国际肿瘤学杂志,2016,43(11):845-847.
[14] Uras IZ,Moll HP,Casanova E. Targeting KRAS Mutant Non-Small-Cell Lung Cancer:Past,Present and Future [J]. Int J Mol Sci,2020,21(12):4325-4332.
[15] Yang CY,Yang JC,Yang PC. Precision Management of Advanced Non-Small Cell Lung Cancer [J]. Annu Rev Med,2020,71(5):117-136.
[16] 尤静,杨丹,李东明,等.同步推量调强放疗在局部晚期非小细胞肺癌中的应用[J].中国肺癌杂志,2019,22(11):22-27.
[17] 祝情情,谢超,宋宝,等.节拍化疗在晚期非小细胞肺癌治疗中的应用[J].国际肿瘤学杂志,2019,46(6):374-377.
[18] 张艳萍.阿帕替尼对晚期非小细胞肺癌疗效和安全性的Meta分析[D].合肥:安徽医科大学,2019.
[19] 贺庆,高华,王军志.肿瘤免疫治疗相关PD-1分子表达的调节因素分析[J].中国新药杂志,2020,25(13):1478-1484.
[20] 闫睿.化疗与靶向治疗顺序对晚期进展性非小细胞肺癌患者进展及生存期的影响[J].中国现代医生,2021,59(1):73-76.
[21] 金倩晨,姜佳宁,吕金燕,等.阿特珠单抗、贝伐珠单抗联合化疗治疗EGFR-TKIs耐药后晚期非小细胞肺癌1例并文献复习[J].中国医药科学,2021,11(4):239-241.
[22] 陈轩,李真斌,易向军.多西他赛联合安罗替尼二线治疗晚期非小细胞肺癌的有效性及安全性分析[J].中国当代医药,2021,28(11):109-111,127.
[23] Liu J,Liu Q,Li Y,et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer:an open-label phase Ⅱ trial [J]. J Immunother Cancer,2020,8(1):696-703.
[24] 曾志艳,李庆艳,屈雪玲,等.卡瑞利珠单抗致乳腺反应性毛细血管瘤1例[J].中国肿瘤临床,2021,48(13):701-702.
[25] Lickliter JD,Gan HK,Voskoboynik M,et al. A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia [J]. Drug Des Devel Ther,2020,14(8):1177-1189.
[26] 位变,王华庆,柳凤亭,等.PD-1抑制剂卡瑞利珠单抗治疗恶性肿瘤引发反应性皮肤毛细血管增生二例[J].中华皮肤科杂志,2021,54(3):252-253.
[27] 刘金,曹刚,张根山,等.卡瑞利珠单抗联合阿帕替尼治疗D-TACE后进展的中晚期肝癌的初步疗效及安全性分析[J].中华医学杂志,2021,101(29):2304-2309.
[28] Zhou CC,Gao GH,Wu FY,et al. A phase Ⅰb study of SHR-1210 plus apatinib for heavily previously treated advanced non-squamous non-small cell lung cancer (NSCLC) patients [J]. J Clin Oncol,2018,36(15):2101-2107.
[29] 袁国盛,何伟猛,胡晓云,等.卡瑞利珠单克隆抗体联合阿帕替尼二线治疗不可切除肝细胞癌的临床疗效及安全性分析:一项多中心回顾性研究[J].中华肝脏病杂志,2021,29(4):326-331.
[1]
陈幸 王晓莉. 帕罗西汀对比度洛西汀治疗抑郁症的系统评价及药物经济学分析 [J]. 中国医药导报, 2021, 18(9): 140-144.
[2]
张晓林 雷茹茹 张燕茹 陈怀安. 输尿管尿路上皮癌行完全腹腔镜下肾输尿管全长切除、膀胱袖状切除术的治疗效果 [J]. 中国医药导报, 2021, 18(9): 81-85.
[3]
马东升1 叶芳2 徐玉秀1 王萌1 郭力1. 减低剂量的地西他滨治疗骨髓增生异常综合征患者1例并文献复习 [J]. 中国医药导报, 2021, 18(9): 176-178,184.
[4]
郑桂丽 梁秀菊 董敏 时延龙 魏炎 仲晨. PD-1抑制剂联合FOLFOX4化疗方案治疗晚期胃癌的效果 [J]. 中国医药导报, 2021, 18(8): 98-101.
[5]
黄秀芳1 原向伟2▲ 秦英2 陈忠羡2. 干扰素α对人骨肉瘤U2OS细胞化疗敏感性的影响 [J]. 中国医药导报, 2021, 18(6): 23-26.
[6]
高健 徐细明 陈嘉羽. 阿瑞匹坦联合地塞米松及多拉司琼治疗肺小细胞癌EP方案化疗致恶心呕吐的效果 [J]. 中国医药导报, 2021, 18(5): 88-92,108.
[7]
迟旭1 刘丽姣2 王野1 王岩3. 复方斑蝥胶囊联合GP化疗治疗晚期非小细胞肺癌的效果 [J]. 中国医药导报, 2021, 18(5): 97-100,112.
[8]
韩富华1,2 欧阳嘉慧1 陶庄3 詹敏2 乔丹丹2 陈文洁2 孙林娟2 缴秀珍4. 奥氮平对比利培酮治疗阿尔茨海默病精神行为症状有效性与安全性的meta分析 [J]. 中国医药导报, 2021, 18(35): 80-87.
[9]
向燕君1 谭明英1▲ 张正芳2 潘薇3. 晚期乳腺癌保乳术后化疗患者希望水平与归因方式的相关性 [J]. 中国医药导报, 2021, 18(35): 113-116.
[10]
邹朦朦 许蔚▲. 基于IMB模型的干预模式在胃癌术后化疗患者护理中的应用 [J]. 中国医药导报, 2021, 18(33): 173-176,188.
[11]
王文儒 唐旭东. 自噬在恶性血液病防治过程中的研究进展 [J]. 中国医药导报, 2021, 18(33): 35-39.
[12]
木巴拉克·依克拉木1 曹艳2 张翠萍3. 多学科协作管理模式对改善乳腺癌化疗患者失志症候群、希望水平及社会支持的影响 [J]. 中国医药导报, 2021, 18(32): 163-166.
[13]
汪丹丹 李亚林 万元. BiPAP联合肺表面活性物质治疗新生儿呼吸窘迫综合征的临床效果及安全性 [J]. 中国医药导报, 2021, 18(30): 114-117.
[14]
史湖波1 徐祎慧2. 非小细胞肺癌新辅助治疗的进展 [J]. 中国医药导报, 2021, 18(3): 43-47.
[15]
潘恩媛1 夏琴2. 贝伐珠单抗联合化疗治疗非小细胞肺癌的效果及对T细胞亚群、免疫功能的影响 [J]. 中国医药导报, 2021, 18(29): 118-121.